Targets › SMN1
8 programs from 6 companies in 11 trials: 7 Phase 1, 3 Phase 3, 1 Phase 4; Neurology, Other; next expected readout Dec 2026.
Open in Phaseline: the race on SMN1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Onasemnogene Abeparvovec-brve (ITVISMA®) Adeno-associated virus serotype 9 (AAV9) delivering SMN1 gene | SMN1 | Phase 4 | Spinal Muscular Atrophy | May 2032 |
| GeneCradle | GC101 Self-complementary AAV9 delivering codon-optimized SMN coding sequence | SMN1 | Phase 3 | SMA - Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy; SMA II | Dec 2026 |
| Novartis | onasemnogene abeparvovec Survival motor neuron protein exogenous gene | SMN2, SMN1 | Phase 3 | Spinal Muscular Atrophy (SMA) | Apr 2031 |
| Novartis | Onasemnogene Abeparvovec Survival motor neuron protein exogenous gene | SMN2, SMN1 | Phase 3 | Spinal Muscular Atrophy Type I | Dec 2035 |
| Lantu Biopharma | vesemnogene lantuparvovec AAV-mediated SMN1 gene delivery | SMN1 | Phase 1 | Spinal Muscular Atrophy | Oct 2027 |
| Gemma Biotherapeutics | GB221 Gene therapy delivering functional SMN1 gene via AAV vector to motor neurons | SMN1 | Phase 1 | Spinal Muscular Atrophy Type I | Dec 2028 |
| Lanyue Biotech (Hangzhou) | SKG0201 Injection rAAV vector-based gene therapy delivering SMN1 gene | SMN1 | Phase 1 | Spinal Muscular Atrophy 1 | May 2029 |
| Biocad | ANB-004 Adeno-associated viral vector carrying the SMN gene | SMN1 | Phase 1 | Spinal Muscular Atrophy (SMA) | Aug 2030 |
Spinal Muscular Atrophy (3) Spinal Muscular Atrophy Type I (2) Spinal Muscular Atrophy (SMA) (2) SMA - Spinal Muscular Atrophy (1) Spinal Muscular Atrophy Type 3 (1) SMA II (1) Spinal Muscular Atrophy 1 (1)
other (7), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.